GSK's Jideytro Wins FDA Approval for ROS1-Positive Lung Cancer, First in Class from Nuvalent Deal
GSK sits 40% above its 52-week low of $36.34.
Summary
GSK's Jideytro (zidesamtinib) received FDA approval for previously treated ROS1-positive NSCLC, the first approval from the recently completed Nuvalent acquisition. The drug showed a 44% response rate with durable benefits, arriving two months ahead of schedule and strengthening GSK's growing oncology portfolio.
Key Events · Product Development and Regulatory · GSK
-
FDA Approval of Jideytro
Jideytro (zidesamtinib) approved for adults with previously treated ROS1-positive NSCLC, two months ahead of the September 18, 2026 target action date.
-
Efficacy and Safety Data
In 117 patients, objective response rate was 44% (95% CI: 34-53%); duration of response at 6 and 12 months was 82% and 69%, respectively. Most common adverse reactions (≥15%) included oedema, peripheral neuropathy, constipation, fatigue, and dyspnoea.
-
First Lung Cancer Approval
This is GSK's first approved medicine in lung cancer, derived from the recently completed $10.6 billion Nuvalent acquisition, validating the deal's strategic rationale.
-
Pipeline Momentum
Another Nuvalent asset, neladalkib (NVL-655) for ALK-altered NSCLC, is under FDA review with a target decision date of November 27, 2026; NVL-330 for HER2-altered NSCLC is also in development.
Analysis · GSK · Life Sciences
The FDA approved GSK's Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, marking the company's first lung cancer drug and the first approval from the $10.6 billion Nuvalent acquisition completed just last week. The approval came two months ahead of the September target date, with compelling efficacy data — a 44% objective response rate and durable responses lasting beyond a year in many patients. This validates GSK's oncology strategy and the Nuvalent deal, with another Nuvalent asset (neladalkib) under FDA review for November 2026. The drug addresses a clear unmet need in a younger patient population often resistant to existing therapies, and its brain-penetrant design tackles a key limitation of current treatments.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.5% of the 522 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $50.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $101.4B. The 52-week trading range was $36.34 to $61.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.